Advertisement

Preeclampsia and Renal Disease in Pregnancy: Obstetric Perspective

  • Shelly Soni
  • Michelle Smith-Levitin
Chapter

Abstract

Preeclampsia is a common obstetrical complication that results in serious maternal as well as neonatal morbidity and mortality. It is more common and frequently more severe in patients with underlying renal disease. Management does not differ significantly in patients with preeclampsia superimposed on chronic kidney disease (CKD), but judicious care needs to be taken of fluid status and magnesium toxicities. As we develop further understanding of pathophysiology of the disease, both prevention and treatment are expected to improve.

Keywords

Gestational hypertension  Preeclampsia Eclampsia Chronic hypertension Chronic hypertension with superimposed preeclampsia Renal disease in pregnancy Pregnancy in patients on dialysis 

References

  1. 1.
    National high blood pressure educational program. Bethesda: National Institutes of Health and National Heart, Lung, and Blood Institute, 2000.Google Scholar
  2. 2.
    Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.Google Scholar
  3. 3.
    American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–31.CrossRefGoogle Scholar
  4. 4.
    Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013;209:544.e1–e12.CrossRefGoogle Scholar
  5. 5.
    Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises. Best Pract Res Clin Obstet Gynaecol. 2013;27:877–84.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348:g2301.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ. 2008;336:211–5.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986;155:1011–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991;165:1408–12.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2007;2:543–9.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    van der Graaf AM, Toering TJ, Faas MM, Lely AT. From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? Nephrol Dial Transplant. 2012;27(Suppl 3):iii51–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Hennessy A, Makris A. Preeclamptic nephropathy. Nephrology. 2011;16:134–43.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196:320.e1–7.CrossRefGoogle Scholar
  15. 15.
    Müller-Deile J, Schiffer M. Preeclampsia from a renal point of view: insides into disease models, biomarkers and therapy. World J Nephrol. 2014;3:169–81.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Hirashima C, Ohkuchi A, Arai F, Takahashi K, Suzuki H, Watanabe T, Kario K, Matsubara S, Suzuki M. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2005;28:727–32.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50:1702–3.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre- eclampsia. J Clin Invest. 2003;111:649–58.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52:2682–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Sanchez-Ramos L, Briones DK, Kaunitz AM, Delvalle GO, Gaudier FL, Walker CD. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. Obstet Gynecol. 1994;84:349–53.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Herse F, Dechend R, Harsem NK, et al. Dysregulation of the circulat- ing and tissue-based renin–angiotensin system in preeclampsia. Hypertension. 2007;49:604–11.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB. Angiotensin-(1–7) in normal and preeclamptic pregnancy. Endocrine. 2002;18:239–46.CrossRefGoogle Scholar
  23. 23.
    Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382–7.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med. 1992;326:927–32.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    National Kidney Foundation Practice. Guidelines for chronic kidney disease: evaluation, classification and stratification. Ann Intern Med. 2003;139:137–47.CrossRefGoogle Scholar
  26. 26.
    Hou SH, Grossman SD, Madia N. Pregnancy in women with renal disease and moderate renal insufficiency. Am J Med. 1985;78:185–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Imbasciati E, Pardi G, Capetta P. Pregnancy in women with chronic renal failure. Am J Nephrol. 1986;6:193–8.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996;335:226–32.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Katz AI, Davison JM, Hayslett JP, Simpson M. Pregnancy in women with kidney disease. Kidney Int. 1980;18:192–206.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating GFR in adults without kidney disease. J Am Soc Nephrol. 2003;14:2573–80.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Smith MC, Moran P, Ward MK, Davison JM. Assessment of GFR during pregnancy using the MDRD formula. Br J Obstet Gynaecol. 2008;115:109–12.CrossRefGoogle Scholar
  32. 32.
    Ahmed SB, Bentley-Lewis R, Hollenberg NK, Graves SW, Seely EW. A comparison of prediction equations for estimating GFR in pregnancy. Hypertens Pregnancy. 2009;13:1–13.Google Scholar
  33. 33.
    Strevens H, Wide-Swensson D, Grubb A, Hansen A, Horn T, Ingemarsson I, et al. Serum cystatin-C reflects glomerular endotheliosis in normal, hypertensive and preeclamptic pregnancies. Br J Obstet Gynaecol. 2003;110:825–30.CrossRefGoogle Scholar
  34. 34.
    Alper AB, Yi Y, Webber LS, Pridjian G, Mumuney AA, Saade G, Morgan J, Nuwayhid B, Belfort M, Puschett J. Estimation of glomerular filtration rate in preeclamptic patients. Am J Perinatol. 2007;24(10):569–74.CrossRefGoogle Scholar
  35. 35.
    Hou S. Pregnancy in women with chronic renal disease. N Engl J Med. 1985;312:836–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Jungers P, Chauveau D, Choukroun G, Moynot A, Skhiri H, Houillier P, Forget D, Grünfeld JP. Pregnancy in women with impaired renal function. Clin Nephrol. 1997;47:281–8.PubMedGoogle Scholar
  37. 37.
    Epstein FH. Pregnancy and renal disease. N Engl J Med. 1996;335:277–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis. 1999;33:235–52.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Okendaye I, Abrinko P, Hou S. Registry of pregnancy in dialysis patients. Am J Kidney Dis. 1998;31:766–73.CrossRefGoogle Scholar
  40. 40.
    Jungers P, Houillier P, Forget D, Henry-Amar M. Specific controversies concerning the natural history of renal disease in pregnancy. Am J Kidney Dis. 1991;17:116–22.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Bramham K, Seed PT, Lightstone L, Nelson-Piercy C, Gill C, Webster P, Poston L, Chappell LC. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int. 2016;89:874–85.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Carter J, Child A. Serum uric acid levels in normal pregnancy. Aust N Z J Obstet Gynaecol. 1989;29:313–4.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Rolfo A, Attini R, Tavassoli E, Neve FV, Nigra M, Cicilano M, Nuzzo AM, Giuffrida D, Biolcati M, Nichelatti M, Gaglioti P, Todros T, Piccoli GB. Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study. Dis Markers. 2015;2015:127083.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, Maisel A. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol. 2005;193:450–4.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    D’Anna R, Baviera G, Giordano D, Todarello G, Russo S, Recupero S, Bolignano D, Corrado F. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand. 2010;89:275–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Conrad KP, Davison JM. The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? Am J Physiol Renal Physiol. 2014;306(10):F1121–35.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, Zwinderman AH, Robson SC, Bindels PJ, Kleijnen J, Khan KS. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta- analysis. CMAJ. 2008;178:701–11.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Napolitano R, Melchiorre K, Arcangeli T, Dias T, Bhide A, Thilaganathan B. Screening for pre-eclampsia by using changes in uterine artery Doppler indices with advancing gestation. Prenat Diagn. 2012;32:180–4.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Grobman WA, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet Gynecol. 2012;120:815–22.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25:949–53.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME, FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–7.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Farina A. Biophysical markers for abnormal placentation: first and/or second trimester. Prenat Diagn. 2014;34:628–34.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;(3):CD004454.Google Scholar
  54. 54.
    Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, Rouse DJ, McKenna DS, Clark EA, Thorp JM Jr, Chien EK, Peaceman AM, Gibbs RS, Swamy GK, Norton ME, Casey BM, Caritis SN, Tolosa JE, Sorokin Y, VanDorsten JP, Jain L, NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med. 2016;374:1311–20.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Luders C, Castro MC, Titan SM, De Castro I, Elias RM, Abensur H, Romão JE Jr. Obstetric outcome in pregnant women on long-term dialysis: a case series. Am J Kidney Dis. 2010;56:77–85.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Chou CY, Ting IW, Lin TH, Lee CN. Pregnancy in patients on chronic dialysis: a single center experience and combined analysis of reported results. Eur J Obstet Gynecol Reprod Biol. 2008;136:165–70.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Malik GH, Al-Harbi A, Al-Mohaya S, Dohaimi H, Kechrid M, Shetaia MS, Al-Hassan AO, Quiapos LS. Pregnancy in patients on dialysis – experience at a referral center. J Assoc Physicians India. 2005;53:937–41.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Nadeau-Fredette AC, Hladunewich M, Hui D, Keunen J, Chan CT. End-stage renal disease and pregnancy. Adv Chronic Kidney Dis. 2013;20:246–52.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819–26.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force, Evidence Synthesis No. 112. AHRQ Publication No. 14-05207-EF-1. Rockville: Agency for Healthcare Research and Quality; 2014.CrossRefGoogle Scholar
  61. 61.
    Rolnik D, Wirght D, Poon L, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.CrossRefGoogle Scholar
  62. 62.
    Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014;(6):CD001059.Google Scholar
  63. 63.
    Hofmeyr GJ, Belizán JM, von Dadelszen P, Calcium and Pre-eclampsia (CAP) Study Group. Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG. 2014;121:951–7.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Rumbold A, Duley L, Crowther C, Haslam R. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev. 2008;(1):CD004227.Google Scholar
  65. 65.
    Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH, Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomized placebo-controlled trial. Lancet. 2006;367:1145–54.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS, ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354:1796–806.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    van Oostwaard MF, Langenveld J, Schuit E, Papatsonis DN, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol. 2015;212:624.e1.CrossRefGoogle Scholar
  68. 68.
    Bramham K, Briley AL, Seed P, Poston L, Shennan AH, Chappell LC. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol. 2011;204:512.e1.CrossRefGoogle Scholar
  69. 69.
    Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol. 1985;92:131–40.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, Melbye M, Boyd HA. Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy. JAMA. 2016;315:1026–33.PubMedCrossRefGoogle Scholar
  72. 72.
    Kessous R, Shoham-Vardi I, Pariente G, Sergienko R, Sheiner E. Long-term maternal atherosclerotic morbidity in women with pre-eclampsia. Heart. 2015;101:442–6.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359:800–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Shelly Soni
    • 1
  • Michelle Smith-Levitin
    • 1
  1. 1.Department of Maternal Fetal MedicineDonald and Barbara Zucker School of Medicine at Hofstra/NorthwellManhassetUSA

Personalised recommendations